Lucid Diagnostics’ Initial Public Offering

Friedman Kaplan advised PAVmed Inc. and its majority-owned subsidiary Lucid Diagnostics Inc. on the public offering. Lucid Diagnostics Inc. (Nasdaq: LUCD),  a commercial-stage, cancer prevention medical diagnostics...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here